Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimaprost for residual symptoms after cervical spinal decompression
ChiCTR2500098336Phase 4Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of limaprost in cervical spondylomyelopathy (CSM), Neuralgia and paresthesia (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Neck Disability Index (NDI). Started Mar 2025; status: completed.
02
Drugs
limaprost
03
Conditions
cervical spondylomyelopathy (CSM)Neuralgiaparesthesia
Beyond the preview
Go deeper on ChiCTR2500098336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098336.